Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer

Abstract Adjuvant trastuzumab in HER2+ breast cancer reduces recurrence and mortality, and has been the standard treatment since 2006. The objective was to analyze health outcomes in the real world. Observational, retrospective study of patients with HER2+ breast cancer, stages I–III, treated with a...

Full description

Bibliographic Details
Main Authors: J. Lluch-Gómez, V. Núñez-Álvarez, C. de la Torre-Hita, M. Bernal-Gómez, A. Campini-Bermejo, E. Perdomo-Zaldívar, L. Rodríguez-Pérez, J. Calvete-Candenas, M. J. Martínez-Bautista, E. Benítez-Rodríguez, J. M. Baena-Cañada
Format: Article
Language:English
Published: Nature Portfolio 2023-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-34429-9

Internet

https://doi.org/10.1038/s41598-023-34429-9

Similar Items